The transition of GLP-1 receptor agonist therapies from weekly injections like Ozempic, Wegovy, and Mounjaro to once-daily oral pills could significantly expand access to diabetes and obesity treatment in the Global South. Affecting one in nine people globally between the ages of 20 and 79, diabetes